June 5, 2026
A new proposed White House Office of Management and Budget (OMB) rule that cites PEPFAR as justification for greater political oversight of federal grantmaking puts research in peril; vaccine developments accelerate as the Ebola Bundibugyo outbreak grows; and the US Secretary of State takes questions from multiple Congressional committees about the future of PEPFAR; responding to the Ebola outbreak; support of Gavi, the Vaccine Alliance; and US global health security. The Administration also nominated Johnny Figueroa of Tennessee to serve as Global AIDS Coordinator and issued a new Executive Order making thousands of US government employees easier to fire in continued efforts to dismantle science.
Proposed White House Rule Puts Research in Peril
In an ongoing attempt to decimate and politicize science, the White House Office of Management and Budget (OMB) proposed sweeping new regulations to significantly expand political interference in federal funding decisions across all federal grants, threatening science, global health and the HIV/AIDS response. International scientific partnerships would be broadly discouraged, if not prohibited. Awards could be terminated at any time, for any reason. The rules also dramatically restrict public access to information about federally funded research—from grant funding opportunities to study results to hand-picked selection of research projects by administration officials. Moreover, new rules require “pre-issuance” by senior political appointees in making preliminary decisions for prospective grant proposals, marking a remarkable shift in decision-making power from objective, scientific content experts to ideologically driven loyalists. The proposed rule is currently open for public comment through July 13. Click here to comment or see AVAC’s Action Alert for more instructions.
IMPLICATIONS: These rules, if adopted, would mandate that federally funded science align with a politically motivated “America-First” research agenda aimed at dismantling decades of transformative global collaboration. These rules have the potential to dramatically reshape the trajectory of the entire federal HIV research to rollout continuum—threatening 2030 targets and the pathway to global health equity. Notably, the published proposed rule specifically and falsely references PEPFAR as justification for increased political scrutiny of federal grants, linking HIV and global health programs to a broader debate over federal spending, oversight and executive authority. For the HIV field, these changes could affect the entire research-to-rollout continuum and global partnerships, at a time when scientific collaboration is necessary to achieving 2030 HIV targets and advancing global health equity.
READ:
- Exclusive: HHS is now weighing in on science in NIH grants—Science
- White House plans to vet public grants for ‘American values’ spark broad alarm—The Guardian
- ACTION ALERT: Research in Peril—AVAC
- Summary of Key Changes in OMB’s Proposed Federal Financial Assistance Rule—Elizabeth Ginexi Substack
Race to Develop a Vaccine for the Ebola Bundibugyo Outbreak
This week, CEPI announced up to $62 million to accelerate three Bundibugyo-specific vaccine candidates into clinical testing. This comes as researchers and health officials are exploring whether existing Ebola vaccines and experimental therapies could offer some protection in the meantime. However, scientists warn that the outbreak is exposing a longstanding preparedness gap: despite years of warnings about the threat posed by non-Zaire Ebola strains, no licensed vaccines or therapeutics were available when this outbreak began. STAT reports that according to two former US Centers for Disease Control and Prevention (CDC) staffers, pandemic preparedness plans developed after COVID-19 were discarded under the current administration. And the firings of personnel and dismantled coordination mechanisms have left the US, and thus the global, response more fragmented.
IMPLICATIONS: These developments underscore a recurring lesson from both Ebola and HIV: scientific innovation alone is not enough. Sustained investment in research, surveillance, preparedness and global cooperation before a crisis emerges is essential to protecting health security and accelerating equitable access to lifesaving tools.
- As Ebola outbreak grows, Trump administration veers from previous government playbook—STAT
- Mistrust Spreads With the Ebola Virus in Congo—New York Times
- Only the Right Tests Can Stop This Ebola Outbreak. Congo Has Hardly Any.—New York Times
- Africa CDC and WHO Push Back Against Ebola-Related Travel Restrictions—EcoFin Agency
- NIH cuts weakened network primed to respond to outbreaks like Ebola—STAT
- Desperate to fight Ebola outbreak, Congo weighs using longshot vaccine options—Science
- CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates—CEPI
- Africa’s response to Ebola must be defined by Africa itself—Financial Times
- US commits $13.5M to Kenya as Ebola evacuation plan sparks backlash—Devex
US Congress Questions Secretary of State on Ebola, Gavi and PEPFAR
US Secretary of State Marco Rubio testified for two days this week in front of multiple House and Senate congressional committees to defend the Administration’s Fiscal Year 2027 State Department budget and foreign policy agenda. Rubio was questioned on the Administration’s response to the Ebola Bundibugyo outbreak; future support for Gavi, the Vaccine Alliance; and the restructuring of US foreign assistance, among other topics. In response to concerns that no single official is leading the Ebola response (something he harshly criticized the Obama administration for in 2014–15 when he was a senator), Rubio said the Administration is considering a dedicated coordinator. He also noted that the US may re-engage with Gavi amid the growing outbreak. During testimony at the Senate Foreign Relations Committee hearing, public health and HIV activists were arrested while interrupting his speech, saying “Rubio’s cuts kill people with AIDS. PEPFAR saves lives.”
IMPLICATIONS: The hearings are bringing to light competing forces between the Administration and its intent to align its global health engagement with an “America First” strategy and concerns from Congress and the people about the consequences for outbreak preparedness, PEPFAR and HIV programs and international health security. Rubio’s comments on Gavi suggest that the worsening Ebola outbreak may be forcing a reassessment of recent moves away from multilateral health partnerships, particularly as Gavi plays a critical role in outbreak response and the development of potential Ebola vaccines. For the HIV field, the hearings reinforced that debates over PEPFAR, vaccine financing and global health security are increasingly interconnected, with Congress needing to step-up its oversight role to serve as a key arena for determining the future direction of US global health leadership.
- US to Re-Engage With Gavi Vaccine Alliance Amid Ebola Outbreak Rubio Says—Reuters
- Activists Arrested Protesting Secretary Rubio’s New Attacks on Lifesaving Global AIDS and Health Programs During Senate Foreign Relations Committee Testimony—Health GAP
- First Look at a Full America First Global Health Strategy Country Implementation Plan: Not Exactly a Plan—Emily Bass Substack
- What Rubio’s 2 days on the Hill foretell for 2028—Politico
- Rubio Suggests US Return to Global Vaccine Program in Rebuke of Kennedy—New York Times
- White House may appoint Ebola lead, Rubio tells lawmakers—Devex
New Executive Order Makes Thousands of Federal Employees Easier to Fire
A new US Executive Order (EO) was issued implementing “Schedule Policy/Career”, a category of employment that removes protections from approximately 8,000 federal employees in positions deemed to influence policy. The order expands the concept behind the Administration’s earlier “Schedule F” proposal, making it easier to fire career officials and replace merit-based protections with “at-will employment”. Federal agencies, including the Department of Health and Human Services (HHS), are expected to identify employees whose roles involve policy development, regulations or other policy-related functions.
IMPLICATIONS: Making non-political and career civil servants focused on policymaking easier to remove – with no legal recourse – is another step in the broader effort to centralize authority within the executive branch and shift toward greater political oversight of science, research and public health. Implementation of this EO could deprive the federal government of large swaths of built-up institutional memory, public health knowledge, and scientific expertise and be replaced by ideologues in alignment with Administration’s policy agenda. This is particularly a threat to the wide range of public health and research agencies under the purview of HHS, including NIH and its institutes, CDC, HRSA, FDA, among others.
READ:
- Some HHS employees just got easier to fire—Politico
- Trump Makes It Easier to Fire Thousands of Federal Workers—TIME
- Trump formalizes move of career federal workers into ‘at will&rsqrsquo; roles—The Hill
What We’re Reading
- Scientific Breakthroughs and Political Retreat Set the Stage for a Crucial Global Moment in the Fight Against HIV/AIDS—Global Dispatches
- First Look at a Full America First Global Health Strategy Country Implementation Plan: Not Exactly a Plan—Emily Bass Substack
- Conversations on Planes: A Q&A with mike Reid—Global Development Interrupted
- Trump Wants Minerals, Health Data for Aid. African Nations Are Pushing Back.—Wall Street Journal
- ACTG Launches HIV Cure Study Evaluating Novel Approach Targeting the HIV Reservoi
- All you need to know about the jab that could dramatically reduce new HIV infections in SA—Spotlight SA
- Elton John, Sen. Frist: We’ve come too far to let AIDS win—USA Today
- HIV Forty-Five Years Later—Lights! Cameras! Equity Substack
- This is Why You Don’t Slash Humanitarian Aid—New York Times
- Courts may deliver the anti-vaccine movement’s biggest win—Washington Post
- NIH Selects Dr. Steven Schiff as Director of Fogarty International Center, Associate Director for International Research—National Institutes of Health
- House spending panel proposes slight raise for NIH in 2027—Science